



The 20th Anniversary of Pharmaceuticals – Recent Advances in Hybridization and Bioconjugation for Drug Discovery

Guest Editors:

Message from the Guest Editors

Dr. Angela Patricia Hernandez

Department of Pharmaceutical Sciences: Pharmaceutical Chemistry, Faculty of Pharmacy, University of Salamanca, CIETUS, IBSAL, 37007 Salamanca, Spain

Dr. M^a Ángeles Castro

Department of Pharmaceutical Sciences: Pharmaceutical Chemistry, Faculty of Pharmacy, University of Salamanca, CIETUS, IBSAL, 37007 Salamanca, Spain

This Special Issue entitled “Recent advances in hybridization and bioconjugation for drug discovery” aims to cover the advances that are being made in relation to the combination of molecules of any nature to improve their therapeutic properties. Contributions may concern the design and obtaining of novel entities, focusing on the merging of different approaches. Some examples of such approaches could be molecular hybrids based on drugs with different mechanisms of action, multitarget therapies, antibody–drug conjugates, or nanoparticle-based conjugates. Chemical strategies for conjugate coupling as the use of linker modulators or crosslinking agents are also considered, as well as the biological evaluation of the new emerging agents that can demonstrate the connection and synergy between the components of the pharmaceutical entity. Thus, this Special Issue invites all researchers in the pharmaceutical and biological chemical field to publish their outstanding work on hybridization and bioconjugation.

Deadline for manuscript submissions:

30 June 2024





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com